Tong, T. M. L. http://orcid.org/0000-0002-7381-6858
van der Kooij, M. K.
Speetjens, F. M.
van Erkel, A. R.
van der Meer, R. W.
Lutjeboer, J.
van Persijn van Meerten, E. L.
Martini, C. H.
Zoethout, R. W. M.
Tijl, F. G. J.
Blank, C. U.
Burgmans, M. C.
Kapiteijn, E.
Funding for this research was provided by:
Bristol-Myers Squibb (Not applicable)
Delcath Systems Inc. (Not applicable)
Article History
Received: 3 June 2021
Accepted: 16 January 2022
First Online: 13 February 2022
Declarations
:
: This trial has been approved by the Medical Research Ethics Committee of Leiden, The Hague, and Delft and has been registered under NL69508.058.19. Written informed consent is obtained from patients before study inclusion.
: Not applicable.
: E. Kapiteijn has served as an advisory board member for Bristol-Myers Squibb. This contribution has been paid to the institution. The other authors declare no conflict of interest.